Skip to main content
Print Save

Generic Auvelity Availability

Last updated on Sep 6, 2023.

Auvelity is a brand name of bupropion/dextromethorphan, approved by the FDA in the following formulation(s):

AUVELITY (bupropion hydrochloride; dextromethorphan hydrobromide - tablet, extended release;oral)

  • Manufacturer: AXSOME
    Approval date: August 18, 2022
    Strength(s): 105MG;45MG [RLD]

Has a generic version of Auvelity been approved?

No. There is currently no therapeutically equivalent version of Auvelity available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Auvelity. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Patent 10,058,518

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 10,064,857

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 10,080,727

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 10,092,560

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 10,092,561

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 10,105,327

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 10,105,361

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 10,251,879

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 10,463,634

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 10,512,643

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 10,548,857

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 10,596,167

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 10,772,850

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 10,780,064

    Patent expiration dates:

    • January 7, 2040
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 10,780,066

    Patent expiration dates:

    • November 9, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 10,786,469

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 10,786,496

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 10,799,497

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 10,806,710

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 10,864,209

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 10,874,663

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 10,874,664

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 10,874,665

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 10,881,624

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 10,881,657

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 10,894,046

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 10,894,047

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 10,898,453

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 10,925,842

    Patent expiration dates:

    • January 7, 2040
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 10,933,034

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 10,940,124

    Patent expiration dates:

    • January 7, 2040
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 10,945,973

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 10,966,941

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 10,966,942

    Patent expiration dates:

    • January 7, 2040
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 10,966,974

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 11,020,389

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 11,058,648

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 11,090,300

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 11,096,937

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 11,123,343

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 11,129,826

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 11,141,388

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 11,141,416

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 11,147,808

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 11,185,515

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 11,191,739

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
      ✓ 
      Drug product
  • Patent 11,197,839

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
      ✓ 
      Drug product
  • Patent 11,207,281

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 11,213,521

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 11,229,640

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 11,234,946

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 11,253,491

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 11,253,492

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 11,273,133

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 11,273,134

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 11,285,118

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 11,285,146

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 11,291,638

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 11,291,665

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 11,298,351

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 11,298,352

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 11,311,534

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 11,344,544

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 11,357,744

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 11,364,233

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 11,382,874

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 11,419,867

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 11,426,370

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 11,426,401

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 11,433,067

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
      ✓ 
      Drug product
  • Patent 11,439,636

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 11,478,468

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 11,497,721

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 11,510,918

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 11,517,542

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 11,517,543

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 11,524,007

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 11,524,008

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 11,534,414

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
      ✓ 
      Drug product
  • Patent 11,541,021

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 11,541,048

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 11,596,627

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 11,617,728

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 11,617,747

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO INCREASE DEXTROMETHORPHAN PLASMA LEVELS
  • Patent 11,717,518

    Patent expiration dates:

    • January 20, 2043
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPRION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 11,730,706

    Patent expiration dates:

    • January 23, 2043
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 8,569,328

    Patent expiration dates:

    • October 29, 2033
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
      ✓ 
      Drug product
  • Patent 9,168,234

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 9,198,905

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 9,205,083

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 9,238,032

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 9,278,095

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 9,314,462

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 9,370,513

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 9,375,429

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 9,408,815

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 9,421,176

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 9,457,023

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 9,457,025

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 9,474,731

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 9,486,450

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 9,700,528

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 9,700,553

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 9,707,191

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 9,763,932

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 9,861,595

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 9,867,819

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  • Patent 9,968,568

    Patent expiration dates:

    • November 5, 2034
      ✓ 
      Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • August 18, 2025 - NEW PRODUCT

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer